Screener
Viridian Therapeutics, Inc. VRDN Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001590750-26-000018
FAQ
- What is Viridian Therapeutics, Inc.'s cash & equivalents?
- Viridian Therapeutics, Inc. (VRDN) reported cash & equivalents of $164.99M in Q2 2026.
- How has Viridian Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Viridian Therapeutics, Inc.'s cash & equivalents increased by 40.6% year-over-year, from $117.32M to $164.99M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Viridian Therapeutics, Inc.'s cash & equivalents has grown at a 35.9% compound annual growth rate (CAGR), from $45.9M to $212.38M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Viridian Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude